Current Illinois CancerCare Clinical Trials

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Study Number: ADXS-503-101

Study Summary:
To evaluate the safety and tolerability of ADXS-503, administered as monotherapy in Part A and in combination with pembrolizumab in Part B, and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD). As well, to characterize the preliminary anti-tumor activity of ADXS-503, administered in combination with pembrolizumab in Part C, per RECIST v1.1.

Status: Open

Part B (low dose) and Part C only open at this time

Study Coordinator(s)
  • Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
  • Jessica, 309-243-3615, jjones@illinoiscancercare.com
  • Amanda , 309-243-3663, amullery@illinoiscancercare.com

Study Link

« Search Again